high
throughput
univers
influenza
b
duplex
realtim
rtpcr
develop
meet
effect
heighten
surveil
diagnost
need
essenti
manag
influenza
infect
outbreak
primer
probe
design
target
highli
conserv
region
matrix
protein
influenza
nucleoprotein
influenza
b
optim
use
highthroughput
lightcycl
ii
system
analyt
sensit
specif
character
use
rna
transcript
dilut
serial
archiv
noninfluenza
respiratori
virus
profici
test
sampl
eightynin
clinic
sampl
test
parallel
exist
influenza
b
monoplex
assay
valid
duplex
assay
appli
prospect
clinic
specimen
later
subtyp
april
emerg
influenza
b
variant
necessit
inclus
addit
modifi
probe
influenza
b
revalid
revis
protocol
lower
detect
limit
assay
copi
pcr
crossreact
noninfluenza
respiratori
viru
profici
test
materi
identifi
correctli
parallel
test
reveal
overal
agreement
routin
applic
assay
reveal
high
sensit
specif
detect
influenza
influenza
b
assay
c
q
valu
correl
well
preand
postrevis
protocol
influenza
r
b
r
revis
protocol
detect
three
addit
novel
influenza
b
variant
case
specimen
report
previous
influenza
b
neg
inhous
assay
offer
highli
sensit
specif
option
laboratori
seek
expand
influenza
test
capac
high
throughput
univers
influenza
b
duplex
realtim
rtpcr
develop
meet
effect
heighten
surveil
diagnost
need
essenti
manag
influenza
infect
outbreak
primer
probe
design
target
highli
conserv
region
matrix
protein
influenza
nucleoprotein
influenza
b
optim
use
highthroughput
lightcycl
ii
system
analyt
sensit
specif
character
use
rna
transcript
dilut
serial
archiv
noninfluenza
respiratori
virus
profici
test
sampl
eightynin
clinic
sampl
test
parallel
exist
influenza
b
monoplex
assay
valid
duplex
assay
appli
prospect
clinic
specimen
later
subtyp
april
emerg
influenza
b
variant
necessit
inclus
addit
modifi
probe
influenza
b
revalid
revis
protocol
lower
detect
limit
assay
copi
pcr
crossreact
noninfluenza
respiratori
viru
profici
test
materi
identifi
correctli
parallel
test
reveal
overal
agreement
routin
applic
assay
reveal
high
sensit
specif
detect
influenza
influenza
b
assay
c
q
valu
correl
well
preand
postrevis
protocol
influenza
r
b
r
revis
protocol
detect
three
addit
novel
influenza
b
variant
case
specimen
report
previous
influenza
b
neg
inhous
assay
offer
highli
sensit
specif
option
laboratori
seek
expand
influenza
test
capac
april
novel
swineorigin
influenza
famili
orthomyxovirida
genu
influenzaviru
emerg
mexico
detect
unit
state
america
dawood
et
al
end
may
spread
countri
worldwid
classif
novel
influenza
viru
pandem
strain
debat
cohen
carter
evan
tang
et
al
prompt
reassess
recent
pandem
prepared
practic
cordovavillalobo
et
al
del
rio
hernandezavila
del
rio
guarner
rizzo
et
al
tay
et
al
import
lesson
identifi
mani
retrospect
studi
import
collect
analyz
dissemin
high
qualiti
surveil
data
inform
diagnost
therapeut
public
health
intervent
cordovavillalobo
et
al
kumar
et
al
rizzo
et
al
sigmundsdottir
et
al
tay
et
al
molecular
test
essenti
surveil
tool
particularli
exist
convent
viral
cultur
immunofluoresc
test
inadequ
detect
emerg
novel
virus
lee
et
al
tay
et
al
sever
realtim
revers
transcript
pcr
rrtpcr
assay
develop
simultan
detect
influenza
b
virus
singletub
format
may
fit
purpos
selvaraju
selvarangan
chen
et
al
huber
et
al
papillardmarech
et
al
shisong
et
al
li
et
al
salez
et
al
howev
robust
assay
character
extens
routin
clinic
sampl
profici
test
materi
sensit
specif
highthroughput
duplex
univers
influenza
b
rrtpcr
method
describ
valid
clinic
specimen
profici
test
materi
qualiti
control
molecular
diagnost
royal
colleg
pathologist
australasia
extern
qualiti
assur
program
studi
approv
local
institut
ethic
review
board
nation
healthcar
group
domainspecif
review
board
refer
number
workflow
respiratori
sampl
collect
process
nation
univers
hospit
singapor
describ
previous
detail
lee
et
al
demograph
detail
patient
summar
tabl
briefli
nasopharyngealnas
swab
collect
ml
univers
transport
medium
copan
diagnost
corona
ca
drygel
swab
pretreat
buffer
salin
pb
kept
process
within
hr
viral
rna
extract
ml
univers
transport
medium
ml
ml
nacetylcystein
use
pretreat
sputumendotrach
aspir
extract
viral
rna
elut
ml
eluent
extract
carri
either
bio
robot
qiasymphoni
autom
platform
qiagen
valencia
ca
use
qiagen
viru
mini
kit
qiasymphoni
virusbacteria
mini
kit
respect
accord
manufactur
instruct
amplif
detect
influenza
b
viral
rna
perform
singl
tube
use
exonucleas
probe
rrtpcr
method
ensur
detect
influenza
b
subtyp
primer
probe
minimum
secondari
structur
design
target
highli
conserv
region
matrix
protein
genbank
access
nucleoprotein
b
north
genbank
access
gene
respect
rrtpcr
perform
lightcycl
ii
system
roch
molecular
diagnost
pleasanton
ca
use
superscript
iii
platinum
onestep
qrtpcr
reagent
kit
invitrogen
carlsbad
ca
reaction
volum
compris
ml
extract
rna
templat
ml
enzym
mix
ml
reaction
mix
mmoll
influenza
forward
primer
mmoll
influenza
revers
primer
mmoll
influenza
probe
mmoll
influenza
b
forward
primer
mmoll
influenza
b
revers
primer
mmoll
influenza
b
origin
probe
primer
probe
purchas
eurogentec
ait
sera
belgium
list
tabl
ii
rrtpcr
initi
revers
transcript
min
initi
denatur
min
follow
amplif
cycl
sec
sec
sec
fluoresc
signal
collect
everi
stage
influenza
b
amplif
signal
curv
analyz
absorpt
wavelength
nm
fam
nm
yellow
yakima
respect
fluoresc
signal
colorcompens
accord
manufactur
recommend
appropri
posit
control
nontempl
control
includ
everi
test
run
specif
assay
evalu
use
archiv
patient
sampl
previous
test
posit
human
metapneumoviru
respiratori
syncyti
viru
parainfluenza
viru
type
coronavirus
profici
test
materi
influenza
b
panel
provid
qualiti
control
molecular
diagnost
royal
colleg
pathologiest
australasia
also
use
assess
assay
perform
addit
silico
analysi
perform
character
specif
influenza
primer
probe
align
oligonucleotid
influenza
sequenc
publish
within
addit
order
assess
capabl
assay
detect
recent
novel
reassort
influenza
sequenc
avail
viru
lindstrom
et
al
download
silico
comparison
agreement
univers
influenza
ab
duplex
assay
exist
modifi
influenza
influenza
b
monoplex
assay
lee
et
al
determin
parallel
test
consecut
clinic
sampl
receiv
routin
test
march
april
sampl
subject
season
subtyp
assay
identif
lee
et
al
upon
complet
initi
evalu
duplex
assay
implement
influenzascreen
assay
nation
univers
hospit
singapor
specimen
test
posit
influenza
use
duplex
assay
subtyp
inhous
develop
dualgen
rrtpcr
lee
et
al
publish
season
subtyp
assay
hkchp
april
routin
applic
laboratorydevelop
assay
novel
influenza
b
variant
genbank
access
number
detect
direct
immunofluoresc
stain
viru
cultur
test
neg
assay
caus
failur
detect
variant
viru
assay
presenc
two
singl
nucleotid
substitut
probe
region
assay
incid
describ
detail
lee
et
al
overcom
addit
probe
fulli
complement
influenza
b
variant
design
tabl
ii
includ
equimolar
amount
origin
probe
final
concentr
mmoll
revis
protocol
test
parallel
origin
method
contain
origin
probe
randomli
select
influenza
b
posit
sampl
c
q
valu
furthermor
clinic
specimen
report
neg
influenza
ab
april
use
origin
method
retest
revis
protocol
posit
sampl
aris
addit
test
subject
sanger
sequenc
confirm
ident
pathogen
amplicon
matrix
protein
influenza
nucleoprotein
influenza
b
clone
clone
vector
invitrogen
transcrib
vitro
rna
transcript
use
ribomax
larg
scale
rna
product
promega
madison
wi
accord
manufactur
instruct
sequenc
clone
plasmid
confirm
direct
sequenc
prior
transcript
synthes
transcript
quantifi
use
nanodrop
uvvi
spectrophotomet
thermo
fisher
scientif
wilmington
de
use
absorpt
wavelength
nm
lower
detect
limit
linear
studi
revis
univers
influenza
b
rrtpcr
assay
perform
triplic
use
transcript
dilut
serial
copiesml
duplex
assay
exhibit
cross
reactiv
toward
noninfluenza
respiratori
virus
archiv
specimen
univers
influenza
ab
assay
also
abl
identifi
correctli
profici
test
materi
provid
qualiti
control
molecular
diagnost
royal
colleg
pathologiest
australasia
silico
analysi
sequenc
univers
influenza
primer
probe
season
viru
sequenc
show
complement
singl
basepair
mismatch
found
near
end
forward
primer
season
end
forward
revers
primer
strain
expect
affect
significantli
perform
assay
clinic
specimen
test
parallel
posit
influenza
use
duplex
assay
one
detect
exist
monoplex
influenza
assay
influenza
posit
case
confirm
season
subtyp
assay
posit
detect
discrep
specimen
identifi
subtyp
assay
overal
percent
agreement
posit
agreement
neg
agreement
influenza
b
detect
duplex
screen
assay
detect
addit
influenza
b
posit
case
n
compar
two
posit
detect
exist
monoplex
influenza
b
method
april
januari
univers
influenza
ab
duplex
assay
test
sampl
period
influenza
influenza
b
influenza
b
coinfect
detect
influenza
posit
case
confirm
season
season
subtyp
posit
agreement
case
detect
subtyp
method
c
q
valu
duplex
assay
although
assay
silico
analysi
abl
detect
reassort
viru
unfortun
posit
sampl
avail
experiment
test
potenti
assay
detect
strain
remain
undetermin
comparison
preand
postrevis
univers
influenza
ab
protocol
show
good
correl
c
q
valu
r
influenza
b
detect
respect
fig
b
previous
influenza
neg
sampl
test
revis
protocol
addit
influenza
sampl
identifi
confirm
sanger
sequenc
lee
et
al
estim
lower
limit
detect
revis
univers
influenza
ab
duplex
assay
similar
influenza
b
copi
pcr
summari
c
q
valu
concentr
copiespcr
provid
tabl
iii
c
q
valu
chang
per
logarithm
concentr
repres
slope
graph
influenza
b
respect
pcr
effici
deriv
formula
e
valu
repres
effici
influenza
influenza
influenza
b
use
univers
influenza
assay
import
identifi
influenza
patient
season
pandem
avian
influenza
virus
known
less
detect
readili
tradit
diagnost
virolog
method
cell
cultur
immunofluoresc
assay
target
highli
conserv
region
continu
evolv
influenza
viru
reliabl
ensur
detect
strain
includ
novel
strain
subsequ
failur
subtyp
patient
season
rais
suspicion
novel
variant
rare
novel
subtyp
perhap
avian
infect
univers
influenza
ab
assay
abl
achiev
better
specif
sensit
compar
exist
monoplex
assay
addit
optim
assay
highthroughput
platform
lightcycl
ii
may
make
applic
diagnost
laboratori
high
workload
discrep
case
undetect
subtyp
assay
like
due
stochast
variat
low
viral
load
approach
lower
limit
detect
assay
quantit
capabl
univers
influenza
assay
demonstr
viral
load
comparison
studi
influenza
season
influenza
singapor
lee
et
al
within
month
april
four
five
influenza
b
posit
sampl
detect
routin
diagnost
test
turn
new
variant
later
name
influenza
potenti
drift
variant
miss
primer
probe
earlier
version
influenza
ab
duplex
screen
assay
redesign
undertaken
lee
et
al
good
correl
c
q
valu
preand
postrevis
protocol
demonstr
perform
redesign
assay
affect
advers
inclus
addit
probe
conclus
duplex
univers
influenza
ab
assay
offer
use
option
laboratori
requir
highthroughput
test
capac
simultan
detect
influenza
b
virus
save
time
cost
mayb
particularli
use
postpandem
influenza
era
heighten
awar
continu
surveil
hospit
clinic
team
commun
gener
practition
may
increas
diagnost
laboratori
workload
assay
also
fulfil
ongo
surveil
need
phase
pandem
prepared
plan
recommend
world
health
organ
addit
demonstr
potenti
least
silico
detect
recent
reassort
viru
